Recently it was shown that Belimumab, a specific inhibitor of BAFF, and atacicept (TACI-immunoglobulin), a receptor molecule for APRIL, effectively ameliorates clinical symptoms in SLE patients [30], [31], [32]. This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.